Objective:

2

To examine the effectiveness of Chinese medicine (CM) Lianhua Qingwen Granule (LHQW) and Jingyin Gubiao Prescription (JYGB) in asymptomatic or mild patients with Omicron infection in the shelter hospital.

Methods:

2

This single-center retrospective cohort study was conducted in the largest shelter hospital in Shanghai

China

from April 10

2022 to May 30

2022. A total of 56

244 asymptomatic and mild Omicron cases were included and divided into 4 groups

i.e.

non-administration group (23

702 cases)

LHQW group (11

576 cases)

JYGB group (12

112 cases)

and dual combination of LHQW and JYGB group (8

854 cases). The length of stay (LOS) in the hospital was used to assess the effectiveness of LHQW and JYGB treatment on Omicron infection.

Results:

2

Patients aged 41–60 years

with nadir cycle threshold (C

T

) value of N gene

<

25

or those fully vaccinated preferred to receive CM therapy. Before or after propensity score matching (PSM)

the multiple linear regression showed that LHQW and JYGB treatment were independent influence factors of LOS (both

P

<

0.001). After PSM

there were significant differences in LOS between the LHQW/JYGB combination and the other groups (

P

<

0.01). The results of factorial design ANOVA proved that the LHQW/JYGB combination therapy synergistically shortened LOS (

P

=0.032).

Conclusions:

2

Patients with a nadir C

T

value

<

25 were more likely to accept CM. The LHQW/JYGB combination therapy could shorten the LOS of Omicron-infected individuals in an isolated environment.